LCN2 and breast carcinoma: Valashedi et al. claimed that CRISPR/Cas9-mediated knockout of LCN2 significantly promoted erastin-mediated ferroptosis and enhanced cisplatin vulnerability in MDA-MB-231 (a kind of human breast cancer cell line) [30].